Regeneron Pharmaceuticals debt-to-equity fundamental analysis lookup allows you to check this and other indicators for Regeneron Pharmaceuticals or any other equity instrument. You can also select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please check also Equity Screeners to view more equity screening tools
Regeneron Pharmaceuticals Debt to Equity Analysis
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Regeneron Pharmaceuticals Debt to Equity Over Time Pattern
Regeneron Pharmaceuticals Debt to Equity Ratio
About Debt to Equity
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging barrowing against the capital invested by the owners.
According to company disclosure Regeneron Pharmaceuticals has Debt to Equity of 7.2%. This is 86.55% lower than that of the Healthcare sector, and 62.81% lower than that of Biotechnology industry, The Debt to Equity for all stocks is 85.22% higher than the company.
Did you try this?
Run Correlation Analysis Now
Reduce portfolio risk simply by holding instruments which are not perfectly correlated